On March 10, 2022 PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, and Cleveland Clinic reported a five-year strategic collaboration that will focus on leveraging PathAI’s quantitative pathology algorithms both to conduct new translational research and for use as clinical diagnostics in multiple disease areas (Press release, PathAI, MAR 10, 2022, View Source [SID1234609922]). This collaborative effort combines PathAI’s AI-based platforms with Cleveland Clinic’s clinical expertise and multi-modal data to unlock a broad implementation of next-generation pathology diagnostics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our commitment is to provide the best possible care for our patients, and it is increasingly clear that AI-powered pathology can radically enhance diagnostic accuracy and treatment selection," said Dr. Brian Rubin, chair of Pathology and Laboratory Medicine Institute at Cleveland Clinic. "By doing this work, we’re able to maximize the value of machine learning for our patients and fuel deeper innovation that can result in better outcomes."

The collaboration will enable the digitization of hundreds of thousands of pathology specimens, creating millions of whole slide images across multiple disease areas. By linking this digital pathology data with clinical and molecular data, Cleveland Clinic and PathAI will have a rich multi-modal dataset to conduct research using PathAI’s technology platform and menu of pathology algorithms. The partnership also will provide educational opportunities for Cleveland Clinic faculty and trainees, with the goal of enabling the development and usage of AI-powered pathology diagnostics to improve patient care. Cleveland Clinic will become an equity holder in PathAI as part of this agreement.

PathAI will gain access to the digitized pathology slides to develop and improve its AI-powered algorithms, as well as clinical information for research and validation purposes all of which have been de-identified to protect patient privacy. Cleveland Clinic’s medical team will provide expertise to ensure algorithms are fit-for-purpose in both clinical and research settings.

"This exciting collaboration accelerates PathAI’s mission to provide precision pathology for everyone. Cleveland Clinic is the ideal partner, with its many leading clinicians, educators, and researchers who are committed to transforming patient care across disease areas," said Dr. Andy Beck, CEO of PathAI. "We see an incredible opportunity to accelerate innovation in precision pathology and to use our strengths to bridge communities in the healthcare ecosystem including patients, biopharma, and academic research."

On March 10, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) reported that it will host a conference call at 8:00 a.m. ET Thursday, March 17, 2022 to report financial results for the year ended December 31, 2021 and discuss recent corporate highlights (Press release, Aldeyra Therapeutics, MAR 10, 2022, View Source [SID1234609921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 132077. A live webcast of the conference call will also be available on the Investors & Media page of the Aldeyra website at View Source After the live webcast, the event will remain archived on the website for 90 days.

On March 10, 2022 Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) reported the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs (Press release, Exscientia, MAR 10, 2022, View Source [SID1234609920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Xcellomics program was created by the two Oxford-based institutions to expedite early-stage drug discovery research – primarily conducted within academic labs – and potentially leverage those outputs to bring therapies to patients sooner. The program offers applicants resources to explore, identify and rapidly advance novel drug targets by leveraging Oxford TDI’s expertise in developing robust, disease-relevant, predictive screening assays and Exscientia’s AI personalised medicine design capabilities.

"Academic research has and will continue to play a critical role in the development and advancement of medicine, and this partnership is a shining example of how industry and academia can come together to bridge a traditional gap in the drug development cycle," said Sir Peter Ratcliffe, FRS, FMedSci, Director of the Oxford TDI within the Nuffield Department of Medicine and winner of the 2019 Nobel Prize in Medicine. "Despite the multitude of advancements in using genetics, genomics, cell and chemical biology to improve target discovery, we believe we’ve only scratched the surface in terms of available assays that could be translated into meaningful therapies for patients."

Assay submissions will be evaluated and selected by the Xcellomics Scientific Committee and will be developed, produced and validated within Oxford TDI’s advanced cell screening facility using a range of phenotypic and functional genomic outputs that leverage Exscientia’s technology platform. The Xcellomics Board provides oversight and is comprised of members from Exscientia and Oxford TDI, and is chaired by Exscientia’s founder and CEO, Andrew Hopkins, DPhil.

Successful projects will be progressed using Exscientia’s proprietary AI-driven platform with the aim of rapidly identifying potential targets for potential new medicine programmes. Therapeutic area focus will rotate every six months, beginning with a focus on oncology and immuno-oncology, although "blue sky" submissions will be accepted on a rolling basis. Data and intellectual property will be co-owned by the researcher and the Xcellomics program.

"Exscientia’s roots started in academia, and we remain committed to supporting and advancing the innovative research happening at these institutions around the world," said Denise Barrault, Director, Portfolio Management at Exscientia. "We believe that our partnership with the University of Oxford Target Discovery Institute will help unearth new science and potentially translate and advance the most promising ideas into tomorrow’s new medicines."

An online informational event will be held Wednesday, March 23 at 1:00 p.m. GMT. More information on the event can be found at : View Source

On March 10, 2022 Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus (SVV-001), reported that it will host a key opinion leader (KOL) webinar titled "Seneca Valley Virus and TEM8" on Wednesday, March 16, 2022 at 2:00pm Eastern Time (Press release, Seneca Therapeutics, MAR 10, 2022, View Source [SID1234609919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webinar will feature presentations from cancer researcher Mihnea Bostina, Ph.D., from the University of Otago and cancer clinician Aman Chauhan, M.D., from the University of Kentucky. Dr. Bostina will discuss the unique characteristics and exquisite solid tumor specificity of SVV-001 in the treatment of solid cancers. He will also discuss the mechanism of SVV receptor selectivity, specifically TEM8, an integrin expressed primarily on the surface of solid tumor cells. In multiple, well controlled clinical trials, TEM8 was shown to be an important adverse prognostic indicator of survival of patients with a variety of solid tumors. Dr. Chauhan will review three prior human clinical trials performed with intravenously delivered SVV-001 to patients having one of several solid cancer indications. He will also present new data on SVV’s profound ability to synergize with checkpoint inhibitors in animal models. Dr. Chauhan will discuss the Company’s upcoming Phase I/II randomized trial design in patients with neuroendocrine neoplasms that have SVV-001 sensitivity based on the SVV Companion Diagnostic.

Dr. Paul Hallenbeck, President and Chief Scientific Officer at Seneca Therapeutics will give a brief presentation on the history of SVV-001. He will also discuss two new programs in development including the enablement of multiple intravenous administration with SVV and a significant pipeline of armed SVV constructs.

A live question-and-answer session will follow. To register for the event, please click here.

On March 10, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported that it will support an industry-sponsored satellite symposium titled, "Multi-disciplinary Approach to Personalized Medicine, Optimizing Therapeutic Outcomes," at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Therapeutics Conference, held as an in person meeting from March 10-12 in New Orleans, Louisiana, USA (Press release, ITM Isotopen Technologien Munchen, MAR 10, 2022, View Source [SID1234609918]). The educational symposium will take place on March 12, from 11:40 am to 12:00 pm CST, and is part of the conference program and free to all conference attendees. The event will feature expert speakers, nuclear medicine physician Dr. Thomas Hope, University of California, San Francisco and medical oncologist Dr. Namrata Vijayvergia, Fox Chase Cancer Center in Philadelphia. ITM will also host a commercial exhibition booth during the conference to showcase its portfolio of high-quality radioisotopes and laboratory equipment already available in the U.S. to the global precision oncology community.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to contributing to the discussion at the SNMMI Therapeutics Conference, which brings together leading scientists, clinicians and industry professionals that share the goal of improving the lives of patients through the advancement of nuclear medicine," said Steffen Schuster, CEO of ITM. "Radiomolecular precision therapeutics are part of the next frontier in targeted cancer therapy and our symposium will provide expert insights into the current status of clinical research and development."

Symposium & Speaker Details:
The symposium will be held in a conversational format featuring the perspectives of leading experts, Dr. Thomas Hope, a nuclear medicine physician, and Dr. Namrata Vijayvergia, a medical oncologist, as they discuss the importance of targeted radiomolecular therapeutics in oncology. Focus will be placed on current and future cross-departmental approaches and their contribution to earlier diagnosis and improved outcomes for patient living with cancer.

Dr. Thomas Hope is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California. His main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors.

Dr. Namrata Vijayvergia is an Assistant Professor of Hematology and Oncology and Assistant Chief of GI Medical Oncology at Fox Chase Cancer Center in Philadelphia, PA. She is a GI Medical Oncologist with a focus on neuroendocrine tumors and has research interest in developing new treatment paradigms for these cancers.

All conference participants are cordially invited to attend the symposium. Speakers will be available for a Q&A session at the end of the event.

About Targeted Radionuclide Therapy
Targeted Radionuclide Therapy is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, like receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, thereby destroying tumor tissue. The highly precise localization is designed to enable targeted treatment with minimal impact to healthy surrounding tissue.